Reviva Pharmaceuticals Holdings Stock Revenue

RVPH Stock  USD 1.24  0.10  8.77%   
Reviva Pharmaceuticals Holdings fundamentals help investors to digest information that contributes to Reviva Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Reviva Stock. The fundamental analysis module provides a way to measure Reviva Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Reviva Pharmaceuticals stock.
Last ReportedProjected for Next Year
The current Current Deferred Revenue is estimated to decrease to about 2.2 M. The current Cost Of Revenue is estimated to decrease to about 579.8 K.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Reviva Pharmaceuticals Holdings Company Revenue Analysis

Reviva Pharmaceuticals' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Revenue

 = 

Money Received

-

Discounts and Returns

More About Revenue | All Equity Analysis

Historical and Projected quarterly revenue of Reviva

Projected quarterly revenue analysis of Reviva Pharmaceuticals provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Reviva Pharmaceuticals match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Reviva Pharmaceuticals' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Competition

Based on the latest financial disclosure, Reviva Pharmaceuticals Holdings reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.

Reviva Revenue Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Reviva Pharmaceuticals' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Reviva Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Reviva Pharmaceuticals by comparing valuation metrics of similar companies.
Reviva Pharmaceuticals is currently under evaluation in revenue category among its peers.

Reviva Pharmaceuticals Institutional Holders

Institutional Holdings refers to the ownership stake in Reviva Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Reviva Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Reviva Pharmaceuticals' value.
Shares
Blackrock Inc2024-06-30
102.9 K
State Street Corp2024-06-30
71.4 K
Northern Trust Corp2024-09-30
57.7 K
Susquehanna International Group, Llp2024-06-30
41 K
Morgan Stanley - Brokerage Accounts2024-06-30
35.9 K
Sound Income Strategies2024-09-30
30 K
Group One Trading, Lp2024-06-30
29.4 K
Two Sigma Investments Llc2024-09-30
21.4 K
Emc Capital Management(tx)2024-09-30
18.4 K
Armistice Capital, Llc2024-09-30
3.2 M
Woodline Partners Lp2024-06-30
1.6 M

Reviva Fundamentals

About Reviva Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Reviva Pharmaceuticals Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Reviva Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Reviva Pharmaceuticals Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Reviva Pharmaceuticals is a strong investment it is important to analyze Reviva Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Reviva Pharmaceuticals' future performance. For an informed investment choice regarding Reviva Stock, refer to the following important reports:
Check out Reviva Pharmaceuticals Piotroski F Score and Reviva Pharmaceuticals Altman Z Score analysis.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Reviva Pharmaceuticals. If investors know Reviva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Reviva Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.08)
Return On Assets
(2.34)
Return On Equity
(17.95)
The market value of Reviva Pharmaceuticals is measured differently than its book value, which is the value of Reviva that is recorded on the company's balance sheet. Investors also form their own opinion of Reviva Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reviva Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reviva Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reviva Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reviva Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Reviva Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reviva Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.